Company / Current Liabilities
Taysha Gene Therapies, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$26.6M
FY2025
5-year range
$26.2M / $62.8M
FY2021-FY2025
Trend
+1.2%
vs FY2024
Sector context
#180 of 213
Health Care
What the data says
Taysha Gene Therapies, Inc.'s current liabilities of $27M is lower than 85% of companies in the Health Care sector (FY2025). Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $27M.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of +30.1%.
Improved from $37M to $27M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -24.9%
- 5-Year CAGR
- +30.1%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 213This company $26.6M Sector average $1.6B
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +30.1%, indicating consistent growth.
- In FY2025, current liabilities increased 1.2% year-over-year.
- Ranks #180 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.6M | +1.2% |
| FY2024 | $26.2M | -28.6% |
| FY2023 | $36.8M | -41.5% |
| FY2022 | $62.8M | +21.3% |
| FY2021 | $51.7M | +625.9% |
| FY2020 | $7.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026